Summary
0.74 0.01(0.68%)09/06/2024
FRTX (FRTX)
FRTX (FRTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.68 | 7.64 | -7.14 | 27.07 | 43.22 | -55.53 | 0.00 | -91.52 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.74 | |
| Open | 0.74 | |
| High | 0.74 | |
| Low | 0.74 | |
| Volume | 102 | |
| Change | 0.01 | |
| Change % | 0.68 | |
| Avg Volume (20 Days) | 101,490 | |
| Volume/Avg Volume (20 Days) Ratio | 0.00 | |
| 52 Week Range | 0.45 - 3.14 | |
| Price vs 52 Week High | -76.59% | |
| Price vs 52 Week Low | 63.33% | |
| Range | 5.63 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
06/17 16:05 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court
02/14 12:47 EST - globenewswire.com
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
12/27 16:05 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the “Special Meeting”) to seek stockholder approval of the liquidation and dissolution of the Company (the “Dissolution”) and the plan of liquidation and dissolution (the “Plan of Dissolution”).
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the “Special Meeting”) to seek stockholder approval of the liquidation and dissolution of the Company (the “Dissolution”) and the plan of liquidation and dissolution (the “Plan of Dissolution”).
12/19 17:18 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company's common stock now is quoted on the OTC Pink market under the same trading symbol, “FRTX.” The Company has withdrawn its appeal of Nasdaq's determination to delist the Company's common stock, which will no longer trade on The Nasdaq Capital Market.
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company's common stock now is quoted on the OTC Pink market under the same trading symbol, “FRTX.” The Company has withdrawn its appeal of Nasdaq's determination to delist the Company's common stock, which will no longer trade on The Nasdaq Capital Market.
12/18 08:15 EST - globenewswire.com
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th
Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th
Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension
12/15 16:05 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 27, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 27, 2023 at 10 a.m. MT
12/01 17:00 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 15, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 15, 2023 at 10 a.m. MT
11/17 08:30 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.
11/13 08:30 EST - globenewswire.com
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
09/19 16:01 EST - globenewswire.com
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution
08/25 07:20 EST - investorplace.com
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
08/11 16:01 EST - globenewswire.com
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc.
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc.
07/21 08:00 EST - globenewswire.com
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value
03/08 08:39 EST - investorplace.com
Why Is Fresh Tracks Therapeutics (FRTX) Stock Up 92% Today?
Fresh Tracks Therapeutics (NASDAQ: FRTX ) stock is heading higher on Wednesday after announcing positive results from a Phase 1 clinical trial. That clinical trial covers the use of FRTX-02 to restore immunity balance.
Why Is Fresh Tracks Therapeutics (FRTX) Stock Up 92% Today?
Fresh Tracks Therapeutics (NASDAQ: FRTX ) stock is heading higher on Wednesday after announcing positive results from a Phase 1 clinical trial. That clinical trial covers the use of FRTX-02 to restore immunity balance.
01/11 08:51 EST - pennystocks.com
Best Penny Stocks To Buy? 4 To Watch In January 2023
4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy? 4 To Watch In January 2023
4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
11/13 11:10 EST - seekingalpha.com
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chief Medical Officer Albert Marchio - CFO Conference Call Participants Tim Lugo - William Blair Thomas Flaten - Lake Street Capital Operator Welcome everyone, to the Fresh Tracks Therapeutics Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chief Medical Officer Albert Marchio - CFO Conference Call Participants Tim Lugo - William Blair Thomas Flaten - Lake Street Capital Operator Welcome everyone, to the Fresh Tracks Therapeutics Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
11/10 18:48 EST - zacks.com
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
11/03 16:05 EST - globenewswire.com
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its third quarter financial results on Thursday, November 10th. Company management will host a conference call and webcast at 4:30 p.m. EST that same day to discuss the financial results and recent corporate highlights.
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its third quarter financial results on Thursday, November 10th. Company management will host a conference call and webcast at 4:30 p.m. EST that same day to discuss the financial results and recent corporate highlights.
08/11 18:27 EST - seekingalpha.com
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript
Brickell Biotech, Inc. (NASDAQ:BBI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief Financial Officer Deepak Chadha - Chief R&D Officer Conference Call Participants Ron Mather - Oppenheimer Thomas Flaten - Lake Street Operator Welcome everyone to the Brickell Biotech Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript
Brickell Biotech, Inc. (NASDAQ:BBI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief Financial Officer Deepak Chadha - Chief R&D Officer Conference Call Participants Ron Mather - Oppenheimer Thomas Flaten - Lake Street Operator Welcome everyone to the Brickell Biotech Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
07/01 15:44 EST - pulse2.com
Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced
Brickell Biotech, Inc. (Nasdaq: BBI) announced a 1-for-45 reverse split. These are the details.
Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced
Brickell Biotech, Inc. (Nasdaq: BBI) announced a 1-for-45 reverse split. These are the details.